Genomics of Drug Sensitivity in Cancer |
PI-103
|
Synonyms |
PI-103, PI103, PI 103
|
Targets |
PI3Kalpha, DAPK3, CLK4, PIM3, HIPK2
|
Target pathway |
PI3K/MTOR signaling
|
PubCHEM ID |
9884685
|
Jsmol |
|
Download molecule |
9884685
|
PUBCHEM IUPAC INCHI |
InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2
|
Smiles |
O5(CCN(C1(=NC(=NC2(=C1OC=3(N=CC=CC2=3)))C4(=CC(O)=CC=C4)))CC5)
|
Cluster number |
96
|
calculated LogS |
-5,694
|
Molecular weight |
348,361
|
calculated LogP |
2,5871
|
H-Acceptors |
7
|
H-Donors |
1
|
Ro5 violations |
0
|
Druglikeness |
1,1336
|
DrugScore |
0,522211314899923
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
Low FHMT
|
Fish Toxicity2 |
1,4542
|
Rat Acute Toxicity |
2,4327
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2+
|
Caco-2 Permeability2 |
0,9656
|
P-glycoprotein Substrate |
Non-substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Non-inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,3513
|
AMES Toxicity |
AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-2,8609
|